[1]
|
Viprakasit, V. and Ekwattanakit, S. (2018) Clinical Classification, Screening and Diagnosis for Thalassemia. Hematolo-gy/Oncology Clinics of North America, 32, 193-211. https://doi.org/10.1016/j.hoc.2017.11.006
|
[2]
|
Yamamoto, J., Ito, T., Yamaguchi, Y., et al. (2022) Discovery of CRBN as a Target of Thalidomide: A Breakthrough for Progress in the Development of Protein Degraders. Chemical Society Reviews, 51, 6234-6250.
https://doi.org/10.1039/D2CS00116K
|
[3]
|
贾宏声, 李现林, 蔡磊, 等. 不同药物治疗强直性脊柱炎的网状Meta分析[J]. 中国组织工程研究, 2021, 25(33): 5404-5412.
|
[4]
|
陈冠亚, 谢晔. 沙利度胺治疗类风湿关节炎的效果观察及对血清Cys-C VEGF水平的影响[J]. 河北医学, 2020, 26(5): 717-721.
|
[5]
|
曹立军, 贺学强, 戴璞, 等. 沙利度胺联合糖皮质激素治疗难治性克罗恩病初探[J]. 现代消化及介入诊疗, 2022, 27(2): 196-200.
|
[6]
|
潘晓兰, 张燕, 骆竹媚. 沙利度胺联合利妥昔单抗治疗对淋巴瘤患者生存质量的影响[J]. 实用医院临床杂志, 2022, 19(1): 22-25.
|
[7]
|
Yang, K., Wu, Y., Zhou, Y., et al. (2020) Thalidomide for Patients with β-Thalassemia: A Multicenter Ex-perience. Mediterranean Journal of Hematology and Infectious Diseases, 12, e2020021. https://doi.org/10.4084/mjhid.2020.021
|
[8]
|
Lu, Y., Wei, Z., Yang, G., et al. (2022) Investigating the Efficacy and Safety of Thalidomide for Treating Patients with β-Thalassemia: A Meta-Analysis. Frontiers in Pharmacology, 12, Arti-cle ID: 814302.
https://doi.org/10.3389/fphar.2021.814302
|
[9]
|
Nag, A., Radhakrishnan, V.S., Kumar, J., et al. (2020) Thalido-mide in Patients with Transfusion-Dependent E-Beta Thalassemia Refractory to Hydroxyurea: A Single-Center Experi-ence. Indian Journal of Hematology and Blood Transfusion, 36, 399-402. https://doi.org/10.1007/s12288-020-01263-2
|
[10]
|
Yassin, A.K. (2020) Promising Response to Thalidomide in Symptomatic β-Thalassemia. Indian Journal of Hematology and Blood Transfusion, 36, 337-341. https://doi.org/10.1007/s12288-019-01231-5
|
[11]
|
Chen, J., Zhu, W., Cai, N., et al. (2017) Thalidomide Induces Haematologic Responses in Patients with β-Thalassaemia. European Journal of Haematology, 99, 437-441. https://doi.org/10.1111/ejh.12955
|
[12]
|
Javed, R., Radhakrishnan, V., Basu, S., et al. (2020) Challenges in Transfu-sion and the Role of Thalidomide in E-β-Thalassemia—A Case Report. Clinical Case Reports, 8, 2208-2210. https://doi.org/10.1002/ccr3.3141
|
[13]
|
Chen, J.-M., Zhu, W.-J., Liu, J., et al. (2021) Safety and Efficacy of Tha-lidomide in Patients with Transfusion-Dependent β-Thalassemia: A Randomized Clinical Trial. Signal Transduction and Targeted Therapy, 6, Article No. 405.
https://doi.org/10.1038/s41392-021-00811-0
|
[14]
|
Begum, M., Hasan, M., Moslem, M., Nahar Fatema Begum, N., et al. (2020) Outcome of Treatment with Thalidomide in Transfusion Dependent Thalassemia Patients: A Prospective Study in a Thalassemia Center, Dhaka, Bangladesh. American Journal of Pediatrics, 6, 168-171. https://doi.org/10.11648/j.ajp.20200603.11
|
[15]
|
Chandra, J., Parakh, N., Sidharth, et al. (2021) Efficacy and Safety of Thalidomide in Patients with Transfusion-Dependent Thalassemia. Indian Pediatrics, 58, 611-616. https://doi.org/10.1007/s13312-021-2254-y
|
[16]
|
Li, Y., Ren, Q., Zhou, Y., et al. (2018) Thalidomide Has a Signif-icant Effect in Patients with Thalassemia Intermedia. Hematology, 23, 50-54. https://doi.org/10.1080/10245332.2017.1354427
|
[17]
|
Chen, Y., Cai, N., Lai, Y., et al. (2020) Thalidomide for the Treatment of Thrombocytopenia and Hypersplenism in Patients with Cirrhosis or Thalassemia. Frontiers in Pharmacol-ogy, 11, Article No. 1137.
https://doi.org/10.3389/fphar.2020.01137
|
[18]
|
Far, M.A.J., Fard, A.D., Hajizamani, S., et al. (2016) Thalidomide Is More Efficient than Sodium Butyrate in Enhancing GATA-1 and EKLF Gene Expression in Erythroid Progenitors De-rived from HSCs with β-Globin Gene Mutation. International Journal of Hematology-Oncology and Stem Cell Research, 10, 37-41.
|
[19]
|
Aerbajinai, W., Zhu, J., Gao, Z., et al. (2007) Thalidomide Induces γ-Globin Gene Expression through Increased Reactive Oxygen Species-Mediated p38 MAPK Signaling and Histone H4 Acetylation in Adult Erythropoiesis. Blood, 110, 2864-2871. https://doi.org/10.1182/blood-2007-01-065201
|
[20]
|
Ren, Q., Zhou, Y.-L., Wang, L., et al. (2018) Clinical Trial on the Effects of Thalidomide on Hemoglobin Synthesis in Patients with Moderate Thalassemia In-termedia. Annals of Hematology, 97, 1933-1939.
https://doi.org/10.1007/s00277-018-3395-5
|
[21]
|
杨焜, 尹晓林, 刘晓冬, 等. 沙利度胺治疗非输血依赖型β地中海贫血患者血液学反应的预测因素[J]. 中国实验血液学杂志, 2022, 30(5): 1519-1526.
|
[22]
|
李丽. 沙利度胺治疗重型β地中海贫血的疗效及安全性[D]: [硕士学位论文]. 广州: 南方医科大学, 2020.
|
[23]
|
Li, X.-Y., Hu, S.-T., Liu, Y., et al. (2021) Efficacy of Thalidomide Treatment in Children with Transfusion Dependent β-Thalassemia: A Ret-rospective Clinical Study. https://doi.org/10.22541/au.161418357.76442615/v1
|
[24]
|
Thein, S.L., Menzel, S., Lath-rop, M., et al. (2009) Control of Fetal Hemoglobin: New Insights Emerging from Genomics and Clinical Implications. Human Molecular Genetics, 18, R216-R223. https://doi.org/10.1093/hmg/ddp401
|
[25]
|
Haj Khelil, A., Morinière, M., Laradi, S., et al. (2011) Xmn I Polymorphism Associated with Concomitant Activation of Gγ and Aγ Globin Gene Transcription on a β0-Thalassemia Chromosome. Blood Cells, Molecules, and Diseases, 46, 133-138. https://doi.org/10.1016/j.bcmd.2010.11.002
|
[26]
|
Weatherall, D.J. (2001) Phenotype-Genotype Relationships in Monogenic Disease: Lessons from the Thalassaemias. Nature Reviews Genetics, 2, 245-255. https://doi.org/10.1038/35066048
|
[27]
|
Yang, K., Wu, Y., Ma, Y., et al. (2020) The Association of HBG2, BCL11A, and HBS1L-MYB Polymorphisms to Thalidomide Response in Chinese β-Thalassemia Patients. Blood Cells, Molecules, and Diseases, 84, Article ID: 102442.
https://doi.org/10.1016/j.bcmd.2020.102442
|
[28]
|
Sankaran, V.G. (2011) Targeted Therapeutic Strategies for Fetal Hemoglobin Induction. Hematology, 2011, 459-465.
https://doi.org/10.1182/asheducation-2011.1.459
|
[29]
|
朱卫健, 何颖, 黄慕芳, 等. 沙利度胺治疗β-地中海贫血外周血miR-223-3p水平变化及临床价值[J]. 临床荟萃, 2022, 37(6): 515-518.
|
[30]
|
黄婉雪, 杨阳, 汪晓辉, 等. 沙利度胺对重型β地中海贫血患者红系细胞γ珠蛋白基因表达及分化的作用研究[J]. 广西医科大学学报, 2021, 38(1): 9-15.
|
[31]
|
Abbasi, J. (2021) Promising Strategies for Sickle Cell Disease and β-Thalassemia. JAMA, 325, 121.
https://doi.org/10.1001/jama.2020.26232
|
[32]
|
Khandros, E., Huang, P., Peslak, S.A., et al. (2020) Understanding Heterogeneity of Fetal Hemoglobin Induction through Comparative Analysis of F and A Erythroblasts. Blood, 135, 1957-1968.
https://doi.org/10.1182/blood.2020005058
|
[33]
|
Shah, S., Sheth, R., Shah, K., et al. (2020) Safety and Effectiveness of Thalidomide and Hydroxyurea Combination in β-Thalassaemia Intermedia and Major: A Retrospective Pilot Study. British Journal of Haematology, 188, e18-e21.
https://doi.org/10.1111/bjh.16272
|
[34]
|
Naithani, R., Jeyaraman, P. and Mahapatra, M. (2020) Alternative Strategies in Thalassemia: Focus on Thalidomide. Indian Journal of Hematology and Blood Transfusion, 36, 227-228. https://doi.org/10.1007/s12288-020-01285-w
|
[35]
|
Bhurani, D., Kapoor, J., Yadav, N., et al. (2021) Experience with Combination of Hydroxyurea and Low-Dose Thalidomide in Transfusion-Dependent Beta Thalassemia Patients. Annals of Hematology, 100, 1417-1427.
https://doi.org/10.1007/s00277-021-04501-3
|
[36]
|
Ansari, S.H., Ansari, I., Wasim, M., et al. (2022) Evaluation of the Combination Therapy of Hydroxyurea and Thalidomide in β-Thalassemia. Blood Advances, 6, 6162-6168. https://doi.org/10.1182/bloodadvances.2022007031
|
[37]
|
Fard, A.D., Hosseini, S.A., Shahjahani, M., et al. (2013) Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy Disorders. International Journal of Hematology-Oncology and Stem Cell Research, 7, 47-54.
|
[38]
|
黄敏婕. 延伸护理提高中重型β-地中海贫血患者治疗依从性的效果[J]. 智慧健康, 2020, 6(16): 193-194.
|
[39]
|
Xiong, F., Sun, M., Zhang, X., et al. (2010) Molecular Epidemiological Survey of Haemoglobinopathies in the Guangxi Zhuang Autonomous Region of Southern China. Clinical Genetics, 78, 139-148.
https://doi.org/10.1111/j.1399-0004.2010.01430.x
|
[40]
|
Che, J., Luo, T., Huang, L., et al. (2022) Magnetic Reso-nance Imaging Quantification of the Liver Iron Burden and Volume Changes Following Treatment with Thalidomide in Patients with Transfusion-Dependent β-Thalassemia. Frontiers in Pharmacology, 13, Article ID: 810668. https://doi.org/10.3389/fphar.2022.810668
|
[41]
|
Khera, S. (2021) Safety: A Primary Concern in Thalidomide Use in Thalassemia. Indian Pediatrics, 58, 1100-1100.
https://doi.org/10.1007/s13312-021-2385-1
|
[42]
|
Jain, M., Chakrabarti, P., Dolai, T.K., et al. (2021) Comparison of Efficacy and Safety of Thalidomide vs Hydroxyurea in Patients with Hb E-β Thalassemia—A Pilot Study from a Ter-tiary Care Centre of India. Blood Cells, Molecules, and Diseases, 88, Article ID: 102544. https://doi.org/10.1016/j.bcmd.2021.102544
|
[43]
|
Gunaseelan, S. and Prakash, A. (2017) Thalidomide-Induced Stroke in a Child with Thalassemia Major. Journal of Pediatric Hematology/Oncology, 39, e519-e520. https://doi.org/10.1097/MPH.0000000000000860
|
[44]
|
Park, S.B., Goldstein, D., Krishnan, A.V., et al. (2013) Chemotherapy-Induced Peripheral Neurotoxicity: A Critical Analysis: CIPN: A Critical Analysis. CA: A Cancer Journal for Clinicians, 63, 419-437.
https://doi.org/10.3322/caac.21204
|
[45]
|
Banach, M., Juranek, J.K. and Zygulska, A.L. (2017) Chemothera-py-Induced Neuropathies—A Growing Problem for Patients and Health Care Providers. Brain and Behavior, 7, e00558. https://doi.org/10.1002/brb3.558
|
[46]
|
Zajączkowska, R., Kocot-Kępska, M., Leppert, W., et al. (2019) Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. International Journal of Molecular Sciences, 20, Article No. 1451. https://doi.org/10.3390/ijms20061451
|
[47]
|
徐革, 连娜琪, 于洋, 等. 化疗药所致周围神经病变发生机制和治疗的研究进展[J]. 医学综述, 2020, 26(18): 3601-3605+3611.
|
[48]
|
谢卫红, 安娜. 黄连解毒汤对多发性骨髓瘤患者外周血Th1/Th2平衡及周围神经病变的影响[J]. 中医学报, 2020, 35(1): 194-198.
|
[49]
|
韩秀华, 赵兰, 张飞飞, 等. 还原型谷胱甘肽预防沙利度胺治疗相关周围神经病变的临床研究[J]. 白血病∙淋巴瘤, 2018, 27(6): 340-343.
|